UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Perioperative Immunotherapy — A KEY toward Improved Outcomes for Early-Stage Lung Cancer?

The New England journal of medicine, 2023-08, Vol.389 (6), p.560-561

Lovly, Christine M.

2023

Link zum Volltext

Verfügbarkeit prüfen

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties

Molecular cancer research, 2018-11, Vol.16 (11), p.1724-1736

2018

Link zum Volltext

Verfügbarkeit prüfen

IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells

Science signaling, 2022-08, Vol.15 (747), p.eabj5879

2022

Link zum Volltext

Verfügbarkeit prüfen

The Role of NF-κB-1 and NF-κB-2-Mediated Resistance to Apoptosis in Lymphomas

Proceedings of the National Academy of Sciences - PNAS, 2006-06, Vol.103 (24), p.9220-9225

2006

Link zum Volltext

Verfügbarkeit prüfen

Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR -Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance

Cancers, 2020-03, Vol.12 (3), p.675

2020

Link zum Volltext

Verfügbarkeit prüfen

The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome

Translational oncology, 2016-04, Vol.9 (2), p.163-165

2016

Link zum Volltext

Verfügbarkeit prüfen

Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review

Translational lung cancer research, 2023-03, Vol.12 (3), p.615-628

2023

Link zum Volltext

Verfügbarkeit prüfen

Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease

JTO clinical and research reports, 2020-06, Vol.1 (2), p.100024-100024, Article 100024

2020

Link zum Volltext

Verfügbarkeit prüfen

Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.1970-1981

2019

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC

JTO clinical and research reports, 2021-03, Vol.2 (3), p.100110-100110, Article 100110

2021

Link zum Volltext

Verfügbarkeit prüfen

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer

Proceedings of the National Academy of Sciences - PNAS, 2022-07, Vol.119 (30), p.1-e2206588119

2022

Link zum Volltext

Verfügbarkeit prüfen

Alignment, segmentation and neighborhood analysis in cyclic immunohistochemistry data using CASSATT

Cytometry. Part B, Clinical cytometry, 2023-09, Vol.104 (5), p.344-355

2023

Link zum Volltext

Verfügbarkeit prüfen

Tumor Heterogeneity and Therapeutic Resistance

American Society of Clinical Oncology educational book, 2016, Vol.36 (36), p.e585-e593

2016

Link zum Volltext

Verfügbarkeit prüfen

Managing Resistance to EFGR- and ALK-Targeted Therapies

American Society of Clinical Oncology educational book, 2017, Vol.37 (37), p.607-618

2017

Link zum Volltext

Verfügbarkeit prüfen

A novel patient-derived cell line originated at the time of crizotinib resistance displays a mesenchymal phenotype

Journal of thoracic oncology, 2016-02, Vol.11 (2), p.S16-S17

2016

Link zum Volltext

Verfügbarkeit prüfen

Correction: An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer

Cancer discovery, 2019-02, Vol.9 (2), p.303-303

2019

Link zum Volltext

Verfügbarkeit prüfen

Melanoma driver mutations and immune therapy

Oncoimmunology, 2016-05, Vol.5 (5), p.e1051299-e1051299

2016

Link zum Volltext

Verfügbarkeit prüfen

MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology

Journal of thoracic oncology, 2016-11, Vol.11 (11), p.S256-S257

2016

Link zum Volltext

Verfügbarkeit prüfen

My Cancer Genome

Cancer genetics, 2014-06, Vol.207 (6), p.289-289

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3862: Defining immune contexture in small cell lung cancer: Implications for immunotherapy

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3862-3862

2020

Link zum Volltext

Verfügbarkeit prüfen

My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information

AMIA Summits on Translational Science proceedings, 2016, Vol.2016, p.112-121

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 316: Parallel activation of MEK as a mechanism of resistance to ALK inhibitor therapy

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.316-316

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 867: EGFR kinase domain duplication (EGFR-KDD) is activated by asymmetric intra-molecular dimerization

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.867-867

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 330: High-throughput drug screens in osimertinib-resistant NSCLC cell lines, using continuous high-content imaging, identify potential co-targets to overcome acquired resistance

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.330-330

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4761: Transcriptomic overview of EML4-ALK lung cancer cells resistant to ALK inhibitors highlights a vulnerability to CDK inhibitors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4761-4761

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 55

Suche als RSS-Feed

Aktive Filter

KollektionSpringer Nature - Connect here FIRST to enable access

Zeitschrift / SerieJournal Of Clinical Oncology

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(54)
Buchkapitel
(1)

Sprache

Englisch
(55)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Perioperative Immunotherapy — A KEY toward Improved Outcomes for Early-Stage Lung Cancer?

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties

IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells

The Role of NF-κB-1 and NF-κB-2-Mediated Resistance to Apoptosis in Lymphomas

Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR -Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance

The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome

Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review

Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease

Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes

Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer

Alignment, segmentation and neighborhood analysis in cyclic immunohistochemistry data using CASSATT

Tumor Heterogeneity and Therapeutic Resistance

Managing Resistance to EFGR- and ALK-Targeted Therapies

A novel patient-derived cell line originated at the time of crizotinib resistance displays a mesenchymal phenotype

Correction: An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer

Melanoma driver mutations and immune therapy

MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology

My Cancer Genome

Abstract 3862: Defining immune contexture in small cell lung cancer: Implications for immunotherapy

My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information

Abstract 316: Parallel activation of MEK as a mechanism of resistance to ALK inhibitor therapy

Abstract 867: EGFR kinase domain duplication (EGFR-KDD) is activated by asymmetric intra-molecular dimerization

Abstract 330: High-throughput drug screens in osimertinib-resistant NSCLC cell lines, using continuous high-content imaging, identify potential co-targets to overcome acquired resistance

Abstract 4761: Transcriptomic overview of EML4-ALK lung cancer cells resistant to ALK inhibitors highlights a vulnerability to CDK inhibitors

Aktive Filter

Suchergebnisse filtern